0RC7 Stock Overview
A biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Hansa Biopharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 22.16 |
| 52 Week High | SEK 57.30 |
| 52 Week Low | SEK 21.68 |
| Beta | 1.55 |
| 1 Month Change | -7.20% |
| 3 Month Change | -25.74% |
| 1 Year Change | -25.69% |
| 3 Year Change | -64.06% |
| 5 Year Change | -69.60% |
| Change since IPO | -46.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RC7 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -4.3% | -2.3% | -2.2% |
| 1Y | -25.7% | -11.7% | 6.8% |
Return vs Industry: 0RC7 underperformed the UK Biotechs industry which returned -11.7% over the past year.
Return vs Market: 0RC7 underperformed the UK Market which returned 6.8% over the past year.
Price Volatility
| 0RC7 volatility | |
|---|---|
| 0RC7 Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0RC7's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0RC7's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 135 | Søren Tulstrup | www.hansabiopharma.com |
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy.
Hansa Biopharma AB (publ) Fundamentals Summary
| 0RC7 fundamental statistics | |
|---|---|
| Market cap | SEK 1.50b |
| Earnings (TTM) | -SEK 806.74m |
| Revenue (TTM) | SEK 171.32m |
8.7x
P/S Ratio-1.9x
P/E RatioIs 0RC7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RC7 income statement (TTM) | |
|---|---|
| Revenue | SEK 171.32m |
| Cost of Revenue | SEK 83.55m |
| Gross Profit | SEK 87.76m |
| Other Expenses | SEK 894.50m |
| Earnings | -SEK 806.74m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Mar 21, 2025
| Earnings per share (EPS) | -11.90 |
| Gross Margin | 51.23% |
| Net Profit Margin | -470.91% |
| Debt/Equity Ratio | -180.7% |
How did 0RC7 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/13 01:01 |
| End of Day Share Price | 2025/03/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hansa Biopharma AB (publ) is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Christian Lee | ABG Sundal Collier Sponsored |
| Madhu Kumar | B. Riley Securities, Inc. |